Phaseline

Companies › Lexicon Pharmaceuticals

Lexicon Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 3 Phase 3, 1 Phase 2, 1 Phase 1; Cardiovascular, Metabolic and endocrine; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sotagliflozin
Sodium/glucose cotransporter 1 inhibitor; Sodium/glucose cotransporter 2 inhibitor
SLC5A1, SLC5A2Phase 3Obstructive Cardiomyopathy, Hypertrophic; Diabetic Nephropathies; Cardiovascular Diseases; Type 1 DiabetesJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06481891SotagliflozinPhase 3Obstructive Cardiomyopathy, HypertrophicCardiovascularJan 2027
NCT06435156SotagliflozinPhase 2Type 1 DiabetesCardiovascularOct 2027
NCT05696366SotagliflozinPhase 1Type 1 DiabetesMetabolic and endocrineJan 2028
NCT06217302SotagliflozinPhase 3Diabetic NephropathiesCardiovascularDec 2028
NCT06082063SotagliflozinPhase 3Cardiovascular DiseasesCardiovascularJul 2029

From the company's SEC filings

Cash and short-term investments of $183m on 2026-09-30; operating cash outflow about $43m a year; runway about 51 months at that burn, to Jan 2031; 4 of 4 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

SLC5A1 (1) SLC5A2 (1)

Companies with the same targets

Colgate Palmolive Vogenx THPharm Boryung Pharmaceutical AstraZeneca Getz Pharma Boehringer Ingelheim Dong-A ST Hangzhou Zhongmei Huadong Pharmaceutical JW Pharmaceutical

Companies built like this

Vogenx Crystalys Therapeutics vTv Therapeutics Madrigal Pharmaceuticals Inhibikase Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.